Prilenia Therapeutics is a clinical stage biotech company developing its lead drug candidate, pridopidine, for Huntington’s Disease and ALS. It was founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders.
Location: Israel, Tel Aviv District, Herzliya
Total raised: $105.5M
Investors 2
| Date | Name | Website |
| 12.01.2023 | Forbion | forbion.co... |
| 23.02.2021 | ALS Invest... | alsinvestm... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.12.2021 | Series B | $43M | - |
| 03.06.2020 | Series A | $62.5M | ALS Invest... |
Mentions in press and media 18
| Date | Title | Description |
| 10.10.2025 | Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress | Prilenia and Ferrer will present five posters at the 2025 HSG Huntington’s Disease (HD) Clinical Research Congress, including new analyses of 2-year data following patients not taking antidopaminergic medicines (ADMs) through both double-bl... |
| 06.10.2025 | Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting | Prilenia and Ferrer will unveil their planned pivotal Phase 3 study of pridopidine in ALS at the upcoming Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) 2025 Annual Meeting, Florida, October 7-10, 2025 Aimed at confirming the en... |
| 25.07.2025 | Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease | NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain--(BUSINESS WIRE)-- Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has r... |
| 28.04.2025 | Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets | NAARDEN, The Netherlands and WALTHAM, Mass., 28 April 2025 --- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s... |
| 19.09.2024 | Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative dise... |
| 12.04.2024 | Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024 | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases... |
| 03.04.2024 | Prilenia Names Jina Swartz, M.D. Ph.D., as Chief Medical Officer | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases... |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative disease... |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease | -Following positive pre-submission meetings with regulators, Prilenia plans to submit its MAA for pridopidine in Huntington’s disease (HD) in mid-2024- -If approved, pridopidine could be commercially available to patients in Europe as early... |
| 28.03.2023 | Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease | PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 |
Show more